Thanks for the heads up from Aaron Wininger of Schwegman
Lundberg & Woessner, shortly after the first drug patent
linkage decision from the Beijing IP Court, the CNIPA also
announced that they have issued their "first" drug patent
linkage decision. It is interesting to feel the heat of the
competition.
The CNIPA's announcement is at the link below:
https://www.cnipa.gov.cn/art/2022/4/25/art_53_175126.html
The drug at issue is oxycodone hydrochloride sustained-release
tablets to relieve severe pain (like those from cancer) of Purdue
Pharma under the brand OxyContin (basically, an opioid painkiller).
The generic applicant is Yichang Renfu Pharmaceutical Industry
Limited Liability Company (Renfu,
宜昌人福药业有限责任公司).
